Skip to main content

Enrique Grande, MD, PhD

Enrique Grande, MD, PhD
Conference Coverage
01/31/2024
Enrique Grande, MD, shared results from the phase 2 CABATEN study, which evaluated the activity and safety of cabozantinib plus atezolizumab among patients with locally advanced or metastatic adrenocortical carcinoma.
Enrique Grande, MD, shared results from the phase 2 CABATEN study, which evaluated the activity and safety of cabozantinib plus atezolizumab among patients with locally advanced or metastatic adrenocortical carcinoma.
Enrique Grande, MD, shared...
01/31/2024
Oncology